A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Trial Details

NCT ID

NCT06925516

Phase

PHASE2

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

• Apatinib and Adebrelimab in Combination With chemotherapy

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• 1\. Provided informed consent and sign the informed consent form;
• 2\. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
• 3\. Histologically or cytologically confirmed ICC;
• 4\. The patient is not a candidate for surgery, or the disease has progressed after prior surgery and/or local treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.